Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas.
Malouf GG, Compérat E, Yao H, Mouawad R, Lindner V, Rioux-Leclercq N, Verkarre V, Leroy X, Dainese L, Classe M, Descotes JL, Barthelemy P, Yacoub M, Rouprêt M, Bernhard JC, Creighton CJ, Spano JP, Su X, Khayat D. Malouf GG, et al. Among authors: barthelemy p. Sci Rep. 2016 Aug 3;6:30988. doi: 10.1038/srep30988. Sci Rep. 2016. PMID: 27484008 Free PMC article.
Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P, Rioux-Leclercq N, Thibault C, Saldana C, Borchiellini D, Chevreau C, Desmoulins I, Gobert A, Hilgers W, Khalil A, Lemoine N, Schlürmann-Constans F, Négrier S. Barthélémy P, et al. Cancer Treat Rev. 2021 Jun;97:102191. doi: 10.1016/j.ctrv.2021.102191. Epub 2021 Apr 9. Cancer Treat Rev. 2021. PMID: 34015728 Free article. Review.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: barthelemy p. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P. Pignot G, et al. Among authors: barthelemy p. Eur Urol Oncol. 2022 Oct;5(5):577-584. doi: 10.1016/j.euo.2022.07.002. Epub 2022 Jul 17. Eur Urol Oncol. 2022. PMID: 35853818
External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88).
Khene ZE, Larcher A, Bernhard JC, Doumerc N, Ouzaid I, Capitanio U, Nouhaud FX, Boissier R, Rioux-Leclercq N, De La Taille A, Barthelemy P, Montorsi F, Rouprêt M, Bigot P, Bensalah K; French Committee of Urologic Oncology. Khene ZE, et al. Among authors: barthelemy p. Eur Urol Open Sci. 2021 Oct 5;33:89-93. doi: 10.1016/j.euros.2021.09.004. eCollection 2021 Nov. Eur Urol Open Sci. 2021. PMID: 34661173 Free PMC article.
408 results